Objective To investigate the correlation and overlaps between PD-L1 expression and
classical genomic aberrations in Chinese lung adenocarcinoma (LADC) patients. Methods …

Background: Programmed cell death ligand 1 (PD-L1) expression with respect to genetic
alternations has not been well established in non-small cell lung cancer (NSCLC) …

Purpose The study aimed to evaluate the clinicopathological and molecular profiles
associated with programmed death ligand 1 (PD-L1) expression in non-small cell lung cell …

Background Programmed death ligand 1 (PD-L1) expression is the current standard
biomarker used to predict non-smallcell lung cancer (NSCLC) response to immunotherapy …

Although many studies have addressed the prognostic value of programmed cell death-
ligand 1 (PD-L1) expression in lung cancer, the results remain controversial. A systematic …

Background Programmed death ligand‐1 (PD‐L1) expression is a well‐known predictive
biomarker of response to immune checkpoint blockade in non‐small cell lung cancer …

Objectives It was reported that programmed cell death-ligand 1 (PD-L1) expression is
associated with smoking and wild-type epidermal growth factor receptor (EGFR) in lung …

Abstract Background PD-1/PD-L1 inhibitors is the important drugs of immunotherapy for
malignant tumors. PD-L1 expression is an important biomarker of selecting patients for ICIs …

Immune checkpoint inhibitors (ICI) targeting programmed cell death-1 or its ligand (PD-L1)
have improved outcomes in non-small cell lung cancer (NSCLC). High tumor PD-L1 …

Background Programmed death ligand-1 (PD-L1) is a predictive marker of anti-programmed
death protein 1 (PD-1)/PD-L1 therapies for non-small cell lung cancer (NSCLC). However …